Boston Scientific Paclitaxel Stent Restenosis Rate Is Zero At Six Months

Results of a 61-patient, three-center German study of Boston Scientific's paclitaxel-coated NIRx coronary stent appear to match the high standards established in recently released drug-coated stent studies sponsored by Johnson & Johnson/Cordis and Cook.